Stockscreener 앱 받기
89.15
0.49%
-0.3802
전일 마감가:
$89.53
열려 있는:
$89.04
하루 거래량:
1.86M
Relative Volume:
0.33
시가총액:
$33.65B
수익:
$4.82B
순이익/손실:
$930.40M
주가수익비율:
38.13
EPS:
2.3381
순현금흐름:
$1.43B
1주 성능:
+7.78%
1개월 성능:
+18.85%
6개월 성능:
+36.89%
1년 성능:
+11.13%
1일 변동 폭
$88.27
$89.75
1주일 범위
$82.09
$89.75
52주 변동 폭
$54.11
$89.75
덱스컴 Stock (DXCM) Company Profile
명칭
Dexcom Inc
전화
(858) 200-0200
주소
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
89.17 | 33.79B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
109.77 | 189.86B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
341.08 | 133.54B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
89.57 | 116.07B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
51.06 | 74.19B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.25 | 53.99B | 6.30B | 1.07B | 1.09B | 1.8406 |
덱스컴 Stock (DXCM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-24 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2026-01-12 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2025-12-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | 개시 | Evercore ISI | In-line |
| 2025-10-21 | 재개 | Stifel | Buy |
| 2025-09-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-08-21 | 개시 | Argus | Buy |
| 2025-06-16 | 개시 | Truist | Buy |
| 2025-05-30 | 개시 | Goldman | Buy |
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-02-03 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | 개시 | Redburn Atlantic | Neutral |
| 2024-03-12 | 개시 | RBC Capital Mkts | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-04-17 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | 개시 | UBS | Buy |
| 2023-01-26 | 개시 | Wolfe Research | Outperform |
| 2022-10-18 | 개시 | Barclays | Equal Weight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-15 | 개시 | Bernstein | Outperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-02-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-01-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-18 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-07-21 | 재개 | Cowen | Outperform |
| 2021-05-28 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Overweight |
| 2021-01-06 | 업그레이드 | UBS | Neutral → Buy |
| 2020-10-02 | 다운그레이드 | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | 재확인 | Piper Sandler | Overweight |
| 2020-05-14 | 개시 | Wells Fargo | Equal Weight |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-11-07 | 재확인 | Canaccord Genuity | Buy |
| 2019-11-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-10-23 | 개시 | Stifel | Buy |
| 2018-11-28 | 개시 | UBS | Neutral |
| 2018-10-19 | 업그레이드 | Goldman | Sell → Neutral |
| 2018-09-12 | 업그레이드 | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | 재확인 | Canaccord Genuity | Buy |
| 2018-07-02 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-05-11 | 개시 | BofA/Merrill | Buy |
| 2018-05-03 | 재확인 | Canaccord Genuity | Buy |
| 2018-04-04 | 개시 | Goldman | Sell |
| 2018-04-04 | 개시 | Guggenheim | Neutral |
| 2018-03-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | 다운그레이드 | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | 재확인 | Wedbush | Outperform |
모두보기
덱스컴 주식(DXCM)의 최신 뉴스
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
E. Ohman J or Asset Management AB Has $7.62 Million Position in DexCom, Inc. $DXCM - MarketBeat
Stronger Q2 Results and Higher 2026 Outlook Might Change The Case For Investing In DexCom (DXCM) - simplywall.st
DexCom stock hits 52-week high at 87.85 USD By Investing.com - Investing.com UK
DexCom Inc (DXCM) Stock Up 3.4% and Still Undervalued -- GF Scor - GuruFocus
DexCom (NASDAQ:DXCM) Reaches New 1-Year HighWhat's Next? - MarketBeat
DexCom stock hits 52-week high at 87.85 USD - Investing.com India
DexCom, Inc. (DXCM) Stock Analysis: Exploring The 10.25% Potential Upside For Investors - DirectorsTalk Interviews
Assenagon Asset Management S.A. Has $46.72 Million Holdings in DexCom, Inc. $DXCM - MarketBeat
DexCom, Inc. $DXCM Stock Position Lifted by Gradient Investments LLC - MarketBeat
DexCom, Inc. $DXCM Shares Sold by Pacer Advisors Inc. - MarketBeat
Beacon Investment Advisory Services Inc. Reduces Stake in DexCom, Inc. $DXCM - MarketBeat
Dexcom Inc (DXCM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
DXCM|Dexcom Inc|Price:84.750|Chg%:+1.730 - TradingKey
DexCom Inc. Stock Sheds 4.9%, Underperforms Market - webull.com
DexCom, Inc. (NASDAQ:DXCM) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
DexCom Inc (DXCM) Shares Fall 4.9% -- What GF Score of 94 Tells Investors - GuruFocus
DexCom Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
DexCom, Inc. (DXCM) Stock Forecasts - Yahoo! Finance Canada
Rathbones Group PLC Reduces Holdings in DexCom, Inc. $DXCM - MarketBeat
Edgestream Partners L.P. Has $981,000 Holdings in DexCom, Inc. $DXCM - MarketBeat
DexCom, Inc. (DXCM) Stock forecasts - Yahoo Finance Singapore
DexCom (NASDAQ:DXCM) Director Mark Foletta Sells 2,000 Shares - MarketBeat
DexCom Inc (DXCM) director’s family trust sells 4,000 shares under 10b5-1 plan - Stock Titan
Class Action Alert: Levi & Korsinsky Reminds DexCom (DXCM) Investors of December 26, 2025 Deadline - The National Law Review
Levi & Korsinsky Urges DexCom (DXCM) Shareholders to Act Before Lead Plaintiff Deadline December 26, 2025 - The National Law Review
DEXCOM INC : ARGUS RESEARCH RAISES TARGET PRICE BY $10 TO $96 - Bitget
Dexcom Inc : Argus Research Raises Target Pri - moomoo.com
DexCom (NASDAQ:DXCM) Stands Out as an Affordable Growth Stock - ChartMill
DexCom Inc (DXCM) Stock Up 4.6% and Still Undervalued -- GF Scor - GuruFocus
Levi & Korsinsky Notifies DexCom, Inc. (DXCM) Shareholders of Cla - The National Law Review
Insider Selling: DexCom (NASDAQ:DXCM) Director Sells 2,000 Shares - MarketBeat
Dexcom Announces Governance Enhancements Ahead of 2026 Investor Day - The National Law Review
DexCom (DXCM) Recently Broke Out Above the 20-Day Moving Average - Yahoo Finance
DexCom (DXCM) Is Up 16.6% After Raising 2026 Revenue Guidance And Margin OutlookHas The Bull Case Changed? - webull.com
DexCom, Inc. (DXCM) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
DexCom: Still A Cautious Buy Following Earnings (NASDAQ:DXCM) - Seeking Alpha
DexCom, Inc. (DXCM) Stock Analysis: Strong Analyst Ratings and Promising 11.20% Potential Upside - DirectorsTalk Interviews
DexCom (NASDAQ:DXCM) Reaches New 52-Week High After Analyst Upgrade - MarketBeat
DexCom, Inc. $DXCM Shares Bought by Glenmede Trust Co. NA - MarketBeat
DexCom Inc. Stock Rises 12.0%, Outperforms Peers - webull.com
Why DexCom (DXCM) Is Up 16.6% After Raising 2026 Outlook And Expanding Type 2 Access - Yahoo Finance
A Look at DexCom Inc (DXCM) After 11.9% Gain -- GF Value $104.93 vs Price $83.45 - GuruFocus
DexCom Inc (DXCM) GF Score of 92/100 Signals Strong Outperforman - GuruFocus
Quantinno Capital Management LP Purchases 144,722 Shares of DexCom, Inc. $DXCM - MarketBeat
Dexcom Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Dexcom Inc 2026: Revenue $1.31B, EPS $0.64— 10-Q Summary - TradingView
Dexcom reports Q2 2026 revenue $1.308B, GAAP net income $249.1M, raises 2026 revenue midpoint - TradingView
DexCom: Q2 Earnings Snapshot - 10TV
DexCom, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - Morningstar
덱스컴 (DXCM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
덱스컴 주식 (DXCM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| FOLETTA MARK G | Director |
Jul 31 '26 |
Sale |
80.00 |
2,000 |
160,000 |
50,852 |
1.40%
자본화:
|
볼륨(24시간):